Open

Coming up

Don't miss

Replay


LATEST SHOWS

MEDIAWATCH

Ukraine politician thrown on rubbish heap

Read more

DEBATE

Holland on his own? - Socialist backbenchers abstain on confidence vote (part 2)

Read more

DEBATE

Holland on his own? - Socialist backbenchers abstain on confidence vote

Read more

THE INTERVIEW

'Iraq wants role for Iran in anti-IS coalition', says foreign minister

Read more

ENCORE!

Margaret Atwood: A Prophetic Writer in Paris

Read more

FOCUS

Italy: The search for missing migrants

Read more

WEB NEWS

News media urged not to show Islamic State group videos

Read more

IN THE PAPERS

Is Valls crying wolf?

Read more

IN THE PAPERS

Prospect of separation from Scotland stirs sadness in England and Wales

Read more

Roche to buy US biotech firm Seragon for up to $1.7 bn

AFP

Swiss pharmaceutical group Roche said Wednesday it was buying Seragon Pharmaceuticals, a US biotechnology firm specialising in a new way to fight breast cancer, in a deal worth up to $1.7 billion (1.2 billion euros)Swiss pharmaceutical group Roche said Wednesday it was buying Seragon Pharmaceuticals, a US biotechnology firm specialising in a new way to fight breast cancer, in a deal worth up to $1.7 billion (1.2 billion euros)

Swiss pharmaceutical group Roche said Wednesday it was buying Seragon Pharmaceuticals, a US biotechnology firm specialising in a new way to fight breast cancer, in a deal worth up to $1.7 billion (1.2 billion euros)Swiss pharmaceutical group Roche said Wednesday it was buying Seragon Pharmaceuticals, a US biotechnology firm specialising in a new way to fight breast cancer, in a deal worth up to $1.7 billion (1.2 billion euros)

Swiss pharmaceutical group Roche said Wednesday it was buying Seragon Pharmaceuticals, a US biotechnology firm specialising in a new way to fight breast cancer, in a deal worth up to $1.7 billion (1.2 billion euros).

Seragon, a privately held outfit located in California, is developing a new generation of treatments for the most common form of breast cancer, Roche said in a statement.

Roche said its Genentech subsidiary would be acquiring Seragon, putting $725 million in cash upfront and adding up to another $1 billion if "certain predetermined milestones" are met. The deal is expected to be sealed by the end of September if anti-trust regulators raise no objection.

Date created : 2014-07-02